Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization Pulse Given Prior To Weekly Intravenous Abraxane™ in Patients With Advanced Solid Tumors

NCT00313599 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT00313599
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00313599 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization Pulse Given Prior To Weekly Intravenous Abraxane™ in Patients With Advanced Solid Tumors
Lead sponsor
University of California, San Francisco
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2006
Completion date
December 31, 2013
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, brain and central nervous system tumors, breast cancer, esophageal cancer, extragonadal germ cell tumor, gastric cancer, lung cancer, ovarian cancer, prostate cancer